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The inhalation rate is important when patients use an inhaler. Dry powder inhalers (DPIs)
require an inhalation rate 430 Lmin1 whereas metered dose inhalers (MDIs) should be
used at o90 Lmin1. Within the setting of a routine clinic, we have measured peak
inhalation flows (PIF) of COPD patients when they used a Diskus (SDSK), Turbuhaler (STBH),
Handihaler (SHAND) and MDI. Subjects were then randomised into trained (VT) and non-
trained (NT) groups. One hundred and sixty-three patients with a mean (S.D.) age and %
predicted FEV1 of 72.5 (9.9) years and 47.8 (22.2)% completed the study. Of the patients,
4.9%, 14.2% and 57.0% inhaled o30 Lmin1 through SDSK, STHB and SHAND, respectively
and 59.5% inhaled 490 Lmin1 with the MDI. Generally, the more severe the COPD, the
slower was their PIF with all inhalers. The MDI PIF values in the VT group (n ¼ 84) post-
training were significantly (po0.001) slower but there was no change for the DPIs. Of the
55 VT patients inhaling 490 Lmin1 through the MDI only 7 (po0.001) inhaled too fast
post-training. Pre-training 3, 15 and 46 VT subjects inhaledo30 Lmin1 through the SDSK,
STBH and SHAND and after training none, 5 and 26 did not inhale faster than this minimum
required rate. Some COPD patients have problems achieving required PIFs through DPIs but
training is useful to help some exceed the minimum required rate despite only small
improvements. The patients found it easier to slow their PIF through the MDI.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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All dry powder inhalers (DPIs) should be used with an
inhalation that is ‘as deep and hard as you can’. This type of
inhalation manoeuvre with a fast initial acceleration rate is
necessary so that the resultant turbulent ‘force’, which
occurs inside the inhaler, can break up the formulation of
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deposited into the lungs as they join the inspired airstream.
The higher the internal ‘force’ that is generated, the better
is the quality of the emitted dose with respect to lung
deposition. Hence, all dry powder inhalers demonstrate
flow-dependent dose emission and this effect is more
pronounced for some DPIs.1 Failure to make a deep and
forcible inhalation at the start of the inhalation from a DPI
increases the likelihood of the dose impacting in the mouth
and throat.2 A study of 10 stable asthmatics and 16 COPD
patients has reported that when they inhaled using a Diskus
and a Turbuhaler there was a significant correlation between
the peak inspiration rate and the slope of the pressure
change across the inhaler with respect to their inhalation
rate during an inhalation.3 The peak inhalation flow (PIF)
through a dry powder inhaler, therefore, is related to the
acceleration rate and hence is a useful parameter that is
easily measured.
There is an inter- and intra-variability of PIF values
achieved by patients when using DPIs4,5 with a link to the
severity of the obstruction.5 When using a DPI, there is a
minimum inhalation rate for clinical response and an
optimal rate for the best results. Studies have shown that
dose emission from the Diskus is only marginally affected by
flow and that it operates effectively at a PIF of 30 Lmin1.6,7
Although the Turbuhaler has been shown to be effective
down to a PIF of 30 Lmin1,8,9 values of 60 Lmin1 provide
optimal delivery.9–11 A flow-dependent dose emission effect
occurs between 20 and 30 Lmin1 for the Handihaler with a
reported fine particle fraction of 16.3% and 21.8% of the
nominal dose, respectively.12 A further report has high-
lighted that dose emission from the Handihaler is deter-
mined by inhalation flow and volume with a fine particle
dose of 27.7% and 38.4% nominal dose at 20 and 30 Lmin1,
and total dose emission of 49.6% and 58.4%.13 In vitro dose
emission studies from the Diskus and Turbuhaler have
focussed on inhalation rates above 28.3 Lmin1. Dose
emission from the Diskus, Handihaler and Turbuhaler is
summarised in Table 1. The data lead to the general
consensus that 30 Lmin1 should be achieved by patients
when they use a DPI.
When using a metered dose inhaler (MDI), the recom-
mended technique includes ‘a slow and deep inhalation’
that is equivalent to a slow vital inspiratory capacity
manouvre. A review has concluded that the PIF when using
an MDI should be below 90 Lmin1.14 Failure to use a slow
and deep inhalation was the most common mistake made by
patients when they used an MDI.15,16Table 1 In vitro dose emission from dry powder inhalers
(values expressed as a % of the nominal dose).
Inhalation flow
(Lmin1)
Fine particle
dose
Total emitted dose
30 60 30 60
Diskus1 14.5 20.7 76 92
Handihaler12 21.8 24.3 55.9 57.3
Turbuhaler1 11.5 23.8 72 88Verbal training of the inhalation technique is recom-
mended.17 Measurement of inhalation profiles has shown
that 7–19% of COPD patients could not generate the required
inspiratory flows through a Turbuhaler whereas they had no
problems with a Diskus.5 These patients were unable to slow
their rate through an MDI. Other studies have shown that
verbal training can slow the inhalation rate of asthmatic
patients when they use an MDI.18
The IN-Check Meter and the IN-Check-Dial (Clement
Clarke International, UK) are useful meters to identify if a
patient has sufficient inspiratory capacity to use a pre-
scribed DPI.4 These meters were introduced before the
widespread use of combination inhalers and long acting
anticholinergics in the management of COPD. We have
therefore measured the resistance of these inhalers so that
modifications could be made to these inhalation meters.
After appropriate adjustment to these devices, to mimic the
resistance of these inhalers, we have used the setting of a
routine clinic to measure the PIF of COPD patients when
they use commonly prescribed DPIs to identify if they can
achieve the required inhalation rates. We have also assessed
if verbal training helps these patients achieve the recom-
mended PIF through each inhaler.
Method
In vitro measurement of the resistance of DPIs
Clark and Hollingworth19 have described the method to
measure the resistance of a DPI using the relationship:
R ¼ Qﬃﬃﬃﬃﬃﬃ
DP
p ,
where Q is the flow rate (Lmin1), DP is the measured
pressure drop across the inhaler (cm H2O) for a set flow rate
and R is the resistance. A schematic design of our method is
shown in Fig. 1. The flow controller to ensure critical (sonic)
flow was the Critical Flow Controller Model TPK (Copley
Scientific Ltd., UK), vacuum flow was provided by a GAST
1023-703Q ER56X pump (Brook Crompton, UK), pressure
drop was measured by a MKS Baraton Type 223B pressure
transducer (MKS Instruments, GmbH) and flow was measured
by a MKS Type 150 Mass-Flo controller (MKS Instruments,
GmbH). The inhaler was positioned in a dry powder dose
emission apparatus (Copley Scientific Ltd., UK) as shown in
Fig. 1. With the inhaler in situ flow rates between 10 and
120 Lmin1 were applied and the pressure drop measured.
The DPIs measured were a Flixotide 500 mg Diskus (Glaxo-
SmithKline), Pulmicort 200 mg Turbuhaler (AstraZeneca),
Seretide 500 Diskus (GlaxoSmithKline), Spiriva Handihaler
(Boehringer Ingelheim) and the Symbicort 200/6 Turbuhaler
(AstraZeneca). These will be referred to as FDSK, PMTBH,
SDSK, SHAND and STBH. They were chosen because they are
all licensed for use in COPD. Five different inhalers of each
DPI device were used and each device was measured on five
occasions. For the Diskus and Turbuhalers, these doses were
after the discharge of the first and last doses together with
those corresponding to a quarter, half and three quarters of
the nominal doses. All doses were discharged to waste at
60 Lmin1 pre-measurement. For the Handihaler measure-
ments were made with a pierced empty capsule in situ.
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Figure 1 Schematic design to measure the resistance of a dry powder inhaler.
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International, such that settings to mimic the resistance of
the above inhalers were available. AEA Technology (UK)
externally tested the modified IN-Check meters. The results
revealed that the resistance of FDSK (Flixotide 500 Diskus)
was identical to that of SDSK (Seretide 500 Diskus) so only
one set of PIF readings were obtained from the patient
study.Patients
Local Research Ethical Committee approval was obtained
and all patients gave signed informed consent. Patients with
a diagnosis of COPD were recruited to the study from the
out-patient clinic. All had to be stable in that they had
received no short course of oral prednisolone and no changes
to their inhaled medication over the previous 4 weeks. Their
FEV1 was measured and their age and height were recorded.
All patients inhaled through the IN-Check Meter set for each
of the inhalers. The maximum rate that can be measured by
the In-Check meter is 120 Lmin1 so all values above this
rate were recorded as this value. This only occurred for the
MDI and although it is not an absolute value, it does provide
information that the inhalation flow is fast.
Patients studied the patient information leaflet for each
inhaled product and were informed that the DPIs should be
inhaled ‘as deep and hard as you can’. When using the MDI
setting patients were instructed to use an inhalation that
was ‘slowly and deep’. To enable patients to understand this
instruction they were informed that they should breathe out
as far as comfortable and then take a slow inhalation to fill
their lungs with air. They were instructed that the inhalation
step should take them at least 5 s to complete. In reality,
this is equivalent to taking a slow vital capacity inhalation.
The order of administration was randomised. Patients
made two separate inhalations with the IN-Check Meter set
for each product and the highest value was recorded. They
were then randomised into a verbally trained (VT) and a
non-trained (NT) group. The NT group repeated the
inhalations exactly as before with the inhaler order
randomised. The trained (VT) group were verbally coun-
selled how to use each inhaled product immediately before
inhalation. A check list was used to ensure that they
completed the inhalation steps recommended in themanufacturer’s Patient Information Sheet provided with
the inhaler. The order of this was also randomised.
Data were tested for normality using the Shapiro–Wilks
test to identify the statistical test to be used. Normal data
were compared using independent t-testing whilst non-
parametric data (PIF data) were described using median
with interquartile ranges and comparisons using the Man-
n–Whitney test. When patients were categorised into mild
(FEV1 50–80% predicted), moderate (30–49%) and severe
(o30%) COPD categories comparisons were made using one-
way analysis of variance (ANOVA) with Bonferroni Correction
or the Kruskal–Wallis test as appropriate. VT patients were
placed into different PIF categories for each inhaler and
changes pre- and post-training were determined by the Chi-
square test.
Results
Resistance
The relationship between the inhalation flow rate (Q) and
the pressure drop (DP) across each DPI is described in Fig. 2
and summarised in Table 2. Data beyond 80 Lmin1 for
SHAND and 100 Lmin1 for the PMTBH and STBH were not
possible to obtain due to the capacity of the vacuum pump.
Patients
Demographic data and PIF values are described in Table 3.
The number of patients in PIF categories for each inhaler is
described in Fig. 3. These highlight that of the 163 patients
59.5% inhaled 490 Lmin1 through the MDI. Also 4.9%,
14.2% and 57.0% inhaled less than 30 Lmin1 through SDSK,
STBH and SHAND. Their PIFs for these DPIs ranged from 20 to
110 Lmin1, 17 to 89 Lmin1 and 13 to 58 Lmin1. 19.6%
inhaled o20 Lmin1 through HAND. The higher the resis-
tance of the DPI, the lower was the PIF. Thirty-six, 65 and 62
patients had mild, moderate and severe COPD. Table 4 and
Fig. 4 reveal that the milder the COPD severity, the faster
was the PIF through all devices.
All comparisons between VT (n ¼ 84) and NT (n ¼ 79)
groups were statistically similar. A summary of pre- and
post-PIFs for each inhaler within the VT and NT groups is
presented in Fig. 5. Statistical analysis revealed that all
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MDI PIFs in the VT group were slower (po0.001) post-
training. Pre-training 55 out of the 84 (21 with mild, 31
moderate and 32 severe COPD) patients in the VT group[P
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Figure 2 The relationship between inhaled flow and the
pressure drop across dry powder inhalers.
Table 2 Resistance of the dry powder inhalers.
Device Mean (CV)
resistance (cm
H2O)
0.5 Lmin1
Inhalation flow
(Lmin1) for a
+P of 4 kPa
Flixotide Diskus 0.078 (0.77) 81.5
Pulmicort
Turbuhaler
0.120 (0.25) 53.1
Seretide Diskus 0.078 (0.32) 82.4
Spiriva
Handihaler
0.158 (5.88) 40.4
Symbicort
Turbuhaler
0.110 (0.50) 58.3
Table 3 Demographic data and PIF values.
All
N 163
Age (years) 72.5 (9.9)
FEV1 (% predicted) 47.8 (22.2)
PIF—peak inhalation flow
(Lmin1)
MDI 110 (75, 120)
PMTBH 45.9 (14.1)
SDSK 57.5 (17.9)
SHAND 28.6 (10.0)
STBH 47.8 (14.7)
All values are mean (S.D.) except PIF for MDI which are median (intinhaled through the MDI with an inhaled flow of
490 Lmin1. Post-training only seven inhaled above this
rate. Similarly, the three patients using the Diskus that
inhaled o30 Lmin1 all exceeded this value post-training
while 10 of the 15 patients that inhaled below this rate with
the Turbuhaler exceeded this value post-training. Twenty of
the 46 patients that inhaled less than 30 Lmin1 through the
Handihaler improved their inhaled flow above this value
post-training. Overall, more patients in the VT group inhaled
slower with the MDI post-training (Chi-square, po0.001) but
there was no change in the numbers for the Diskus. Similar
analysis revealed that post-training more patients inhaled
faster through the Turbuhaler (po0.05) and the Handihaler
(po0.01). In the NT group, changes in the number of
patients inhaling slower or faster were small.
Comparing the change in the PIF for each device pre- and
post-training, in the VT group, between the three severity
groups revealed that the improvements were significant for
the mild patients compared to both the moderate and
severe category patients (all po0.05 except po0.001 forVT group NT group
84 79
71.6 (10.9) 71.5 (12.5)
49.4 (21.3) 46.0 (23.2)
Pre Pre
120 (75, 120) 100 (70, 120)
45.6 (13.9) 46.0 (14.5)
57.3 (17.0) 57.5 (18.8)
28.3 (8.9) 28.9 (10.0)
47.4 (14.4) 48.1 (14.9)
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Figure 3 Number of patients achieving different peak inhala-
tion flow categories when they inhaled through the dry powder
inhalers.
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Figure 4 Mean (S.D.) and median (upper quartile) peak
inhalation flow rates through the DPIs and the MDI, respectively,
by the COPD severity categories.
Table 4 Number of patients achieving a set PIF through each inhaler.
Inhaler device PIF (Lmin1) Mild (N (%)) Moderate (N (%)) Severe (N (%))
MDI 30–59 2 (5.6) 9 (13.8) 6 (9.7)
60–90 6 (16.7) 19 (29.2) 24 (38.7)
490 28 (77.8) 37 (56.9) 32 (51.6)
Diskus 20–29 0 4 (6.2) 4 (6.5)
30–59 15 (41.7) 32 (49.2) 32 (51.6)
60–90 19 (52.8) 26 (40) 24 (38.7)
490 2 (5.6) 3 (4.60) 2 (3.2)
Turbuhaler o20 0 1 (1.5) 3 (4.8)
20–29 1 (2.8) 10 (15.4) 8 (12.9)
30–59 27 (75) 45 (69.2) 42 (67.7)
60–90 8 (22.2) 9 (13.8) 9 (14.5)
Handihaler o20 2 (5.6) 14 (21.5) 16 (25.8)
20–29 11 (30.6) 28 (43.1) 22 (35.5)
30–59 23 (63.9) 23 (35.4) 24 (38.7)
Inhalation flows of COPD patients using inhalers 2399mild v’s severe patients when they used the Turbuhaler).
There was no difference in the PIF changes between the
moderate and severe obstruction categories.
Discussion
When using a dry powder inhaler our results confirm that the
inhalation flow is dependent on the resistance of the device
and the patient’s inspiratory effort. Those with more severe
obstruction inhaled slower and many had problems achiev-
ing the minimum required rate through the dry powder
inhalers. All patients with COPD prescribed a dry powder
inhaler should, therefore, have their peak inhalation flow
through the inhaler checked. For those with a reduced
inspiratory capacity a DPI with a low resistance or an MDI
may be a better alternative.
The patients we studied were stable and it has been
reported that during exacerbations, a patient’s PIF isreduced.20,21 It would be expected therefore that during
COPD exacerbations many patients may have problems
receiving their usual DPI dose and thus a temporary change
to a different device may be useful. In acute exacerbations,
therefore, the usual practice is to deliver drugs to the lungs
by a metered dose inhaler attached to a spacer or a
nebuliser. The Diskus had the lowest resistance of the dry
powder inhalers we tested and hence is the easiest to use
with a fast inhalation rate. The statistical analysis of the
data suggests that the PIF change post-training, in the
trained group, for the Diskus was unchanged and may
suggest that training is not necessary. However, the three
patients that inhaled o30 Lmin1 did improve above this
value post-training and thus for these the resultant
improved dose emission could be clinically significant. No
patient with mild COPD inhaled less than 30 Lmin1 and thus
for this category training them to use the Diskus may not be
necessary.
The Handihaler had the highest resistance and this was
confirmed by the patients’ peak inhalation flows. A previous
study has revealed that all COPD patients could inhale faster
than 20 Lmin1 and so no in vitro dose emission data have
been reported below this value.12 However, this report does
demonstrate flow-dependent dose emission of the fine
particle dose between 20 and 29 Lmin1. Using the routine
setting of an out-patient clinic and even with the instruction
to inhale ‘as deep and hard as you can’ 19.6%, of 163
patients, inhaled o20 Lmin1 and a further 37.4% achieved
a peak inhalation flow between 20 and 29 Lmin1. Although
in abstract form (to date) an in vitro assessment of the
emitted dose has highlighted that dose emission is reduced
below 20 Lmin1.13 COPD patients who report little benefit
from a tiotropium Handihaler should, therefore, have their
inhalation flow checked because the problem may be low
dose emission. Although the IN-Check Dial is not available
with a Handihaler setting, the resistance results suggest that
if the meter is set for the Turbuhaler then flows below about
40 Lmin1 would suggest an inspiratory problem with the
Handihaler (due to an equivalent PIF of o30 Lmin1).
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Figure 5 Mean (S.D.) and median (upper quartile) peak inhalation flows through each DPI and the MDI, respectively, before and
after training in the verbally trained (VT) (a) and the non-trained (NT) (b) groups.
R.A.M. Al-Showair et al.2400A spray version of tiotropium is not available but there is the
suggestion of this drug being formulated in a Respimat
(Boehringer Ingelheim) inhaler.22 Patients with reduced
inspiratory capacity would benefit from this type of product.
We have adapted the method described by Clark and
Hollingworth19 to measure the resistance of a dry powder
inhaler. To check our method we measured the resistance of
the Diskhaler, Rotahaler and Spinhaler and found these
values to be similar to the ones reported by Clark and
Hollingsworth.19 Our combination Diskus and Turbuhaler
resistance values were also similar to those previously
measured.23 Pharmacopoeial methods recommend dose
emission testing of dry powder inhalers to be carried out
using a pressure drop of 4 kPa across the inhaler. The data in
Table 1 highlight that the majority of the inhalation flows
achieved by patients were below this recommended rate for
in vitro testing. Hence, these compendial methods should
consider a recommendation to test dose emission using a
range of different inhalation flows that are representative of
those routinely achieved by patients through the device to
be tested.
The resistance of the fluticasone Diskus was identical to
that of the combination product but this was not the case for
the Turbuhaler. The Mark 2 version of the Turbuhaler is used
for the formulations of the single agents whereas a Mark 3
version is used for the combination products. The appear-
ance of the Mark 3 version is different and its mouthpiece
rotates to remove any dose remaining in the device after an
inhalation. Despite the lower resistance, in the Mark 3
version, inter- and intra-inhaler flow-dependent dose emis-
sion is still a feature of this combination product.24
There is a lot of debate on the optimal inhalation flow
that needs to be achieved when a patient uses an inhaler.
Stepping outside the optimal rate debate, it is generally
accepted that an MDI should be used with an inhalation flow
of less than 90 Lmin1,14 and that patients should achieve a
rate of 430 Lmin1 when using a DPI. Everard et al.2
investigating dose emission from a Turbuhaler, highlighted
that below 30 Lmin1, the sizes of the particles emitted in
the dose are large and thus would most likely impact in the
mouth and throat rather than being deposited into the
lungs. Although this rate is generally accepted as theminimum when using a dry powder inhaler the Handihaler
has much higher resistance and thus the equivalent flow rate
could be lower.
Using values of o90 Lmin1 for the MDI and 430 Lmin1
for DPIs, the results highlight that training patients with
COPD to use their inhaler is beneficial. The value of training
COPD patients to use a Diskus and a Turbuhaler has been
reported.25 In this previous study, patients were not
instructed to inhale ‘as deep and hard as you can’ until
they were trained. In our study, we gave each patient the
information leaflet to study and to ensure they followed the
instructions we did emphasise the fast inhalation with a DPI.
After training although the improvements in the DPI peak
inhalation rates were small they were sufficient to tip the
balance to receiving a dose that was more likely to be of the
quality to be delivered to the lungs rather than coating the
mouth and throat.2
Before training those with mild COPD severity inhaled
faster through the MDI than the other groups. Post-training
these inhalation flows were markedly reduced in all COPD
severity categories. Generally, all patients found the
instructions to reduce their flow through the MDI easier to
achieve than increasing their rate with a DPI. This is due to
the absence of resistance in an MDI. However when using an
MDI, patients readily lapse into a habit of using an incorrect
technique post-training.26 To solve this problem, the value
of a 2Tone Trainer (Canday Medical, UK) to maintain a slow
inhalation flow has been described.18Conclusion
The higher the resistance in an inhaler, the lower is the
patient’s inhalation flow through the device. Furthermore,
the more severe is the COPD obstruction, the slower is the
inhalation flow through an inhaler. Hence, patients with
severe COPD have problems achieving fast inhalation rates
through inhalers with a high resistance. Many COPD patients,
especially those with moderate and severe obstruction,
have problems achieving the minimum inhalation rate
required through a DPI. Training patients to inhale ‘as deep
and as hard as you can’ helps the patient to improve their
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increase in flow through a DPI was relatively small on many
occasions, it was enough to transform the dose from one
that is most likely to be left in the mouth to one that is
deposited into the lungs. Patients found it easier to achieve
the instructions for using a slow inhalation flow with an MDI.
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